New CEO at Rib-X Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Rib-X Pharmaceuticals (US), a development-stage antibiotics company, has named Mark Leuchtenberger president, chief executive officer and a member of the board of directors. The company's former CEO, Dr Susan Froshauer, has been appointed to the newly created role of chief scientific officer. Mr Leuchtenberger was previously president and CEO of Targanta Therapeutics.